Elon Musk has outlined two products being developed by Neuralink, the brain-computer interface company he co-founded, including an experimental implant that he says could allow people who have never experienced sight to see.
In two posts on X on October 30, Musk identified the products as Telepathy and Blindsight, describing them as the company's first and second products respectively.
While Telepathy is designed to let people interact with computers and other humans through neural signals, Blindsight is being developed to create visual perception by communicating directly with the brain. Musk says the latter is ready from an engineering standpoint and is now waiting for regulatory approval.
However, the announcement comes with an important distinction: the technology has not yet demonstrated that it can restore sight in human patients, and Neuralink's own website describes clinical trials for its visual prosthesis as something it intends to launch in the future.
The claims therefore represent an ambitious target for the company, rather than an established medical breakthrough.
Our second product is called Blindsight and it will, as the name suggests, enable even those who are completely blind or have never seen to see.
— Elon Musk (@elonmusk) October 30, 2026
It is ready from an engineering standpoint. Just waiting on regulatory approval. https://t.co/2hPuw6QsnN
Neuralink Telepathy Aims To Make Thought-Based Communication Faster
Musk described Telepathy as a system that will enable 'high-speed communication with computers or humans simply by thinking'. He also made a prediction about its future capabilities, writing that its output bandwidth would 'vastly exceed the fastest human speech or typing in a few years'.
The technology is based on a brain-computer interface (BCI), which records electrical activity from the brain and translates it into commands that external devices can understand. Neuralink's initial focus has been people with paralysis who have difficulty using conventional computer interfaces.
The company has already moved beyond laboratory demonstrations with Telepathy. Its first human participant, Noland Arbaugh, received the implant in January 2024 after becoming paralysed below the shoulders following a diving accident.
He subsequently demonstrated how he could move a computer cursor, play chess and control other digital activities using his thoughts.
In January 2026, Neuralink published an update marking two years since it began human testing. The company reported that 21 participants had enrolled across its clinical trials worldwide, with participants using its technology to play video games, create digital artwork, operate computers and experiment with assistive robotic arms.
One participant, Nick, demonstrated using a robotic arm to serve himself a drink. These remain experimental capabilities rather than features available to all participants.
The company has also been working on communication for people who have lost the ability to speak. Its research includes decoding neural activity associated with intended finger movements to produce text.
In one experiment, participants reached typing speeds of up to 40 words per minute by imagining movements of their fingers, which Neuralink mapped to letters on a virtual keyboard.
Neuralink has separately described its VOICE clinical trial, which is investigating whether neural signals associated with intended speech can be decoded to restore communication for people with severe speech impairments caused by conditions such as ALS or stroke.
Neuralink Blindsight Could Send Visual Information Directly to the Brain
Blindsight takes a different approach from Telepathy because it is designed to stimulate the brain rather than interpret signals to control external devices.
According to Neuralink's explanation of its visual prosthesis, a camera would capture images of the surrounding environment before a wireless connection transmits information to an implant positioned in the brain's visual cortex.
The idea is to bypass the eyes and optic nerves, which normally carry visual information to the brain. This could potentially help people whose visual pathways have been damaged, provided the relevant brain regions remain capable of processing the signals.
Neuralink received Breakthrough Device Designation from the US Food and Drug Administration (FDA) for Blindsight in September 2024. The designation provides opportunities for more frequent interaction with the FDA and prioritised regulatory review.
However, it is not the same as FDA approval, nor does it establish that a device is safe and effective for patients.
There are also considerable scientific challenges. Creating electrical signals in the visual cortex does not automatically reproduce the experience of natural sight. Researchers must establish how much useful visual information an implant can deliver, how the brain interprets those signals and whether recipients can learn to use the resulting visual perceptions.
Musk has previously acknowledged that the earliest version could produce low-resolution vision, comparing the expected experience to Atari graphics. That is a much more limited prospect than restoring normal eyesight, although even basic visual information could potentially help some people navigate their surroundings.
The company's current visual prosthesis webpage invites interested people to join its patient registry and says it will notify them when clinical trials begin in the United States.
This is an important indication of where the programme stands, particularly as Musk's latest statement about engineering readiness does not establish that human testing or regulatory clearance has been completed.
For now, Telepathy has a growing group of human trial participants and documented demonstrations, while Blindsight remains at an earlier stage of clinical development. Whether the latter can deliver useful artificial vision, particularly to people blind from birth, will depend on evidence from future testing rather than the announcement alone.
